-
1
-
-
2542430341
-
The three Es of cancer immunoediting
-
doi:10.1146/annurev.immunol.22.012703.104803
-
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol (2004) 22:329-60. doi:10.1146/annurev.immunol.22.012703.104803
-
(2004)
Annu Rev Immunol
, vol.22
, pp. 329-360
-
-
Dunn, G.P.1
Old, L.J.2
Schreiber, R.D.3
-
2
-
-
79953087601
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
-
doi:10.1016/j.coi.2010.11.013
-
Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2011) 23:286-92. doi:10.1016/j.coi.2010.11.013
-
(2011)
Curr Opin Immunol
, vol.23
, pp. 286-292
-
-
Gajewski, T.F.1
Fuertes, M.2
Spaapen, R.3
Zheng, Y.4
Kline, J.5
-
3
-
-
82555191051
-
Cancer immunology-analysis of host and tumor factors for personalized medicine
-
doi:10.1038/nrclinonc.2011.122
-
Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 8:711-9. doi:10.1038/nrclinonc.2011.122
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 711-719
-
-
Ogino, S.1
Galon, J.2
Fuchs, C.S.3
Dranoff, G.4
-
4
-
-
84871433609
-
Global profiling strategies for mapping dysregulated metabolic pathways in cancer
-
doi:10.1016/j.cmet.2012.09.013
-
Benjamin DI, Cravatt BF, Nomura DK. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab (2012) 16:565-77. doi:10.1016/j.cmet.2012.09.013
-
(2012)
Cell Metab
, vol.16
, pp. 565-577
-
-
Benjamin, D.I.1
Cravatt, B.F.2
Nomura, D.K.3
-
5
-
-
84871030732
-
Bioinformatics for cancer immunology and immunotherapy
-
doi:10.1007/s00262-012-1354-x
-
Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, Galon J, et al. Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother (2012) 61:1885-903. doi:10.1007/s00262-012-1354-x
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 1885-1903
-
-
Charoentong, P.1
Angelova, M.2
Efremova, M.3
Gallasch, R.4
Hackl, H.5
Galon, J.6
-
6
-
-
84855225492
-
The immune score as a new possible approach for the classification of cancer
-
doi:10.1186/1479-5876-10-1
-
Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 10:1. doi:10.1186/1479-5876-10-1
-
(2012)
J Transl Med
, vol.10
, pp. 1
-
-
Galon, J.1
Pages, F.2
Marincola, F.M.3
Thurin, M.4
Trinchieri, G.5
Fox, B.A.6
-
7
-
-
84887022513
-
An evolutionary perspective on anti-tumor immunity
-
doi:10.3389/fonc.2012.00202
-
Klinke DJ II. An evolutionary perspective on anti-tumor immunity. Front Oncol (2012) 2:202. doi:10.3389/fonc.2012.00202
-
(2012)
Front Oncol
, vol.2
, pp. 202
-
-
Klinke I.I, D.J.1
-
8
-
-
84875490185
-
Cancer genome landscapes
-
doi:10.1126/science.1235122
-
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339:1546-58. doi:10.1126/science.1235122
-
(2013)
Science
, vol.339
, pp. 1546-1558
-
-
Vogelstein, B.1
Papadopoulos, N.2
Velculescu, V.E.3
Zhou, S.4
Diaz Jr., L.A.5
Kinzler, K.W.6
-
9
-
-
84880276438
-
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
-
doi:10.1038/nm.3161
-
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 19:747-52. doi:10.1038/nm.3161
-
(2013)
Nat Med
, vol.19
, pp. 747-752
-
-
Robbins, P.F.1
Lu, Y.C.2
El-Gamil, M.3
Li, Y.F.4
Gross, C.5
Gartner, J.6
-
10
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
doi:10.1056/NEJMoa1001294
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363:411-22. doi:10.1056/NEJMoa1001294
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
-
11
-
-
84858758766
-
Adoptive immunotherapy for cancer: harnessing the T cell response
-
doi:10.1038/nri3191
-
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 12:269-81. doi:10.1038/nri3191
-
(2012)
Nat Rev Immunol
, vol.12
, pp. 269-281
-
-
Restifo, N.P.1
Dudley, M.E.2
Rosenberg, S.A.3
-
12
-
-
84860718270
-
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
-
132ra153. doi:10.1126/scitranslmed.3003761
-
Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 4:132ra153. doi:10.1126/scitranslmed.3003761
-
(2012)
Sci Transl Med
, vol.4
-
-
Scholler, J.1
Brady, T.L.2
Binder-Scholl, G.3
Hwang, W.T.4
Plesa, G.5
Hege, K.M.6
-
13
-
-
77953988924
-
Targeting the tumour vasculature: insights from physiological angiogenesis
-
doi:10.1038/nrc2868
-
Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 10:505-14. doi:10.1038/nrc2868
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 505-514
-
-
Chung, A.S.1
Lee, J.2
Ferrara, N.3
-
14
-
-
79251517382
-
Regulation of cancer cell metabolism
-
doi:10.1038/nrc2981
-
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 11:85-95. doi:10.1038/nrc2981
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 85-95
-
-
Cairns, R.A.1
Harris, I.S.2
Mak, T.W.3
-
15
-
-
37549061827
-
Creating immune privilege: active local suppression that benefits friends, but protects foes
-
doi:10.1038/nri2233
-
Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 8:74-80. doi:10.1038/nri2233
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 74-80
-
-
Mellor, A.L.1
Munn, D.H.2
-
16
-
-
0034609968
-
T-cell function and migration. Two sides of the same coin
-
von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med (2000) 343:1020-34.
-
(2000)
N Engl J Med
, vol.343
, pp. 1020-1034
-
-
von Andrian, U.H.1
Mackay, C.R.2
-
17
-
-
2442519018
-
Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation
-
doi:10.1038/nri1351
-
Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol (2004) 4:325-35. doi:10.1038/nri1351
-
(2004)
Nat Rev Immunol
, vol.4
, pp. 325-335
-
-
Ley, K.1
Kansas, G.S.2
-
18
-
-
4544296118
-
T-cell trafficking in asthma: lipid mediators grease the way
-
doi:10.1038/nri1438
-
Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol (2004) 4:711-24. doi:10.1038/nri1438
-
(2004)
Nat Rev Immunol
, vol.4
, pp. 711-724
-
-
Luster, A.D.1
Tager, A.M.2
-
19
-
-
33846246384
-
Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells
-
doi:10.1016/j.immuni.2007.01.002
-
Alon R, Dustin ML. Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells. Immunity (2007) 26:17-27. doi:10.1016/j.immuni.2007.01.002
-
(2007)
Immunity
, vol.26
, pp. 17-27
-
-
Alon, R.1
Dustin, M.L.2
-
20
-
-
84876910443
-
The integration of T cell migration, differentiation and function
-
doi:10.1038/nri3442
-
Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol (2013) 13:309-20. doi:10.1038/nri3442
-
(2013)
Nat Rev Immunol
, vol.13
, pp. 309-320
-
-
Masopust, D.1
Schenkel, J.M.2
-
21
-
-
0026776328
-
An endothelial ligand for l-selectin is a novel mucin-like molecule
-
doi:10.1016/0092-8674(92)90612-G
-
Lasky LA, Singer MS, Dowbenko D, Imai Y, Henzel WJ, Grimley C, et al. An endothelial ligand for l-selectin is a novel mucin-like molecule. Cell (1992) 69:927-38. doi:10.1016/0092-8674(92)90612-G
-
(1992)
Cell
, vol.69
, pp. 927-938
-
-
Lasky, L.A.1
Singer, M.S.2
Dowbenko, D.3
Imai, Y.4
Henzel, W.J.5
Grimley, C.6
-
22
-
-
0027407109
-
Endothelial-leukocyte adhesion molecules
-
doi:10.1146/annurev.iy.11.040193.004003
-
Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol (1993) 11:767-804. doi:10.1146/annurev.iy.11.040193.004003
-
(1993)
Annu Rev Immunol
, vol.11
, pp. 767-804
-
-
Bevilacqua, M.P.1
-
23
-
-
0034812434
-
Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin
-
doi:10.1111/j.1749-6632.2001.tb03706.x
-
Pober JS, Kluger MS, Schechner JS. Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin. Ann N Y Acad Sci (2001) 941:12-25. doi:10.1111/j.1749-6632.2001.tb03706.x
-
(2001)
Ann N Y Acad Sci
, vol.941
, pp. 12-25
-
-
Pober, J.S.1
Kluger, M.S.2
Schechner, J.S.3
-
24
-
-
47949099098
-
Origin and physiological roles of inflammation
-
doi:10.1038/nature07201
-
Medzhitov R. Origin and physiological roles of inflammation. Nature (2008) 454:428-35. doi:10.1038/nature07201
-
(2008)
Nature
, vol.454
, pp. 428-435
-
-
Medzhitov, R.1
-
25
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
doi:10.1016/j.cell.2011.02.013
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
26
-
-
77649193013
-
Immune infiltration in human tumors: a prognostic factor that should not be ignored
-
doi:10.1038/onc.2009.416
-
Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2010) 29:1093-102. doi:10.1038/onc.2009.416
-
(2010)
Oncogene
, vol.29
, pp. 1093-1102
-
-
Pages, F.1
Galon, J.2
Dieu-Nosjean, M.C.3
Tartour, E.4
Sautes-Fridman, C.5
Fridman, W.H.6
-
27
-
-
77954890371
-
Targeting the ANGPT-TIE2 pathway in malignancy
-
doi:10.1038/nrc2894
-
Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer (2010) 10:575-85. doi:10.1038/nrc2894
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 575-585
-
-
Huang, H.1
Bhat, A.2
Woodnutt, G.3
Lappe, R.4
-
28
-
-
58649124493
-
A dialogue between the hypoxia-inducible factor and the tumor microenvironment
-
doi:10.1007/s12307-008-0006-3
-
Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron (2008) 1:53-68. doi:10.1007/s12307-008-0006-3
-
(2008)
Cancer Microenviron
, vol.1
, pp. 53-68
-
-
Dayan, F.1
Mazure, N.M.2
Brahimi-Horn, M.C.3
Pouyssegur, J.4
-
29
-
-
11844254414
-
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
-
doi:10.1126/science.1104819
-
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307:58-62. doi:10.1126/science.1104819
-
(2005)
Science
, vol.307
, pp. 58-62
-
-
Jain, R.K.1
-
30
-
-
0038143145
-
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma
-
doi:10.1038/nrc1092
-
Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer (2003) 3:411-21. doi:10.1038/nrc1092
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 411-421
-
-
Hendrix, M.J.1
Seftor, E.A.2
Hess, A.R.3
Seftor, R.E.4
-
31
-
-
0028924988
-
Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma
-
doi:10.1084/jem.181.2.811
-
Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med (1995) 181:811-6. doi:10.1084/jem.181.2.811
-
(1995)
J Exp Med
, vol.181
, pp. 811-816
-
-
Piali, L.1
Fichtel, A.2
Terpe, H.J.3
Imhof, B.A.4
Gisler, R.H.5
-
32
-
-
0030044629
-
Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors
-
Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res (1996) 56:1111-7.
-
(1996)
Cancer Res
, vol.56
, pp. 1111-1117
-
-
Griffioen, A.W.1
Damen, C.A.2
Martinotti, S.3
Blijham, G.H.4
Groenewegen, G.5
-
33
-
-
0030700761
-
Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors
-
doi:10.1016/S0304-3835(97)00310-8
-
Hellwig SM, Damen CA, Van Adrichem NP, Blijham GH, Groenewegen G, Griffioen AW. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett (1997) 120:203-11. doi:10.1016/S0304-3835(97)00310-8
-
(1997)
Cancer Lett
, vol.120
, pp. 203-211
-
-
Hellwig, S.M.1
Damen, C.A.2
Van Adrichem, N.P.3
Blijham, G.H.4
Groenewegen, G.5
Griffioen, A.W.6
-
34
-
-
41149097574
-
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
-
doi:10.1038/nrc2355
-
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 8:299-308. doi:10.1038/nrc2355
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 299-308
-
-
Rosenberg, S.A.1
Restifo, N.P.2
Yang, J.C.3
Morgan, R.A.4
Dudley, M.E.5
-
35
-
-
67650744372
-
Immune therapy for cancer
-
doi:10.1146/annurev.immunol.021908.132544
-
Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol (2009) 27:83-117. doi:10.1146/annurev.immunol.021908.132544
-
(2009)
Annu Rev Immunol
, vol.27
, pp. 83-117
-
-
Dougan, M.1
Dranoff, G.2
-
36
-
-
80052206084
-
Prognostic and predictive impact of intra-and peritumoral immune infiltrates
-
doi:10.1158/0008-5472.CAN-11-1316
-
Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res (2011) 71:5601-5. doi:10.1158/0008-5472.CAN-11-1316
-
(2011)
Cancer Res
, vol.71
, pp. 5601-5605
-
-
Fridman, W.H.1
Galon, J.2
Pages, F.3
Tartour, E.4
Sautes-Fridman, C.5
Kroemer, G.6
-
37
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
doi:10.1126/science.1129139
-
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. doi:10.1126/science.1129139
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pages, C.6
-
38
-
-
42749085280
-
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer
-
doi:10.1016/j.it.2008.02.003
-
Bellone M, Mondino A, Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol (2008) 29:235-41. doi:10.1016/j.it.2008.02.003
-
(2008)
Trends Immunol
, vol.29
, pp. 235-241
-
-
Bellone, M.1
Mondino, A.2
Corti, A.3
-
39
-
-
0029894219
-
Tumor necrosis factor: function, release and clearance
-
doi:10.1615/CritRevImmunol.v16.i1.10
-
Bemelmans MH, Van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol (1996) 16:1-11. doi:10.1615/CritRevImmunol.v16.i1.10
-
(1996)
Crit Rev Immunol
, vol.16
, pp. 1-11
-
-
Bemelmans, M.H.1
Van Tits, L.J.2
Buurman, W.A.3
-
40
-
-
0023191197
-
Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity
-
Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, et al. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Cancer Res (1987) 47:3707-11.
-
(1987)
Cancer Res
, vol.47
, pp. 3707-3711
-
-
Manda, T.1
Shimomura, K.2
Mukumoto, S.3
Kobayashi, K.4
Mizota, T.5
Hirai, O.6
-
41
-
-
0025212179
-
Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice
-
McIntosh JK, Mule JJ, Travis WD, Rosenberg SA. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res (1990) 50:2463-9.
-
(1990)
Cancer Res
, vol.50
, pp. 2463-2469
-
-
McIntosh, J.K.1
Mule, J.J.2
Travis, W.D.3
Rosenberg, S.A.4
-
42
-
-
41149083660
-
Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed
-
doi:10.1111/j.1600-065X.2008.00619.x
-
ten Hagen TLM, Seynhaeve ALB, Eggermont AMM. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev (2008) 222:299-315. doi:10.1111/j.1600-065X.2008.00619.x
-
(2008)
Immunol Rev
, vol.222
, pp. 299-315
-
-
ten Hagen, T.L.M.1
Seynhaeve, A.L.B.2
Eggermont, A.M.M.3
-
43
-
-
0033950895
-
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
-
Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res (2000) 60:722-7.
-
(2000)
Cancer Res
, vol.60
, pp. 722-727
-
-
Pasqualini, R.1
Koivunen, E.2
Kain, R.3
Lahdenranta, J.4
Sakamoto, M.5
Stryhn, A.6
-
44
-
-
0036468937
-
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells
-
Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res (2002) 62:867-74.
-
(2002)
Cancer Res
, vol.62
, pp. 867-874
-
-
Curnis, F.1
Arrigoni, G.2
Sacchi, A.3
Fischetti, L.4
Arap, W.5
Pasqualini, R.6
-
45
-
-
0033764170
-
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
-
doi:10.1038/81183
-
Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol (2000) 18:1185-90. doi:10.1038/81183
-
(2000)
Nat Biotechnol
, vol.18
, pp. 1185-1190
-
-
Curnis, F.1
Sacchi, A.2
Borgna, L.3
Magni, F.4
Gasparri, A.5
Corti, A.6
-
46
-
-
0036678474
-
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration
-
doi:10.1172/JCI200215223
-
Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest (2002) 110:475-82. doi:10.1172/JCI200215223
-
(2002)
J Clin Invest
, vol.110
, pp. 475-482
-
-
Curnis, F.1
Sacchi, A.2
Corti, A.3
-
47
-
-
45749129790
-
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer
-
doi:10.1002/pros.20775
-
Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, et al. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate (2008) 68:1105-15. doi:10.1002/pros.20775
-
(2008)
Prostate
, vol.68
, pp. 1105-1115
-
-
Bertilaccio, M.T.1
Grioni, M.2
Sutherland, B.W.3
Degl'Innocenti, E.4
Freschi, M.5
Jachetti, E.6
-
48
-
-
84872867897
-
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells
-
doi:10.4161/mabs.22775
-
Marcucci F, Bellone M, Rumio C, Corti A. Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2013) 5:34-46. doi:10.4161/mabs.22775
-
(2013)
MAbs
, vol.5
, pp. 34-46
-
-
Marcucci, F.1
Bellone, M.2
Rumio, C.3
Corti, A.4
-
49
-
-
84857829255
-
Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy
-
doi:10.4049/jimmunol.1101877
-
Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (2012) 188:2687-94. doi:10.4049/jimmunol.1101877
-
(2012)
J Immunol
, vol.188
, pp. 2687-2694
-
-
Calcinotto, A.1
Grioni, M.2
Jachetti, E.3
Curnis, F.4
Mondino, A.5
Parmiani, G.6
-
50
-
-
84872834025
-
Won't you come on in? How to favor lymphocyte infiltration in tumors
-
doi:10.4161/onci.20213
-
Bellone M, Calcinotto A, Corti A. Won't you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology (2012) 1:986-8. doi:10.4161/onci.20213
-
(2012)
Oncoimmunology
, vol.1
, pp. 986-988
-
-
Bellone, M.1
Calcinotto, A.2
Corti, A.3
-
51
-
-
80052203877
-
Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy
-
doi:10.1158/0008-5472.CAN-11-1273
-
Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy. Cancer Res (2011) 71:5881-90. doi:10.1158/0008-5472.CAN-11-1273
-
(2011)
Cancer Res
, vol.71
, pp. 5881-5890
-
-
Dondossola, E.1
Gasparri, A.M.2
Colombo, B.3
Sacchi, A.4
Curnis, F.5
Corti, A.6
-
52
-
-
31544479807
-
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas
-
doi:10.1007/s10637-005-4540-2
-
van Laarhoven HW, Gambarota G, Heerschap A, Lok J, Verhagen I, Corti A, et al. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs (2006) 24:27-36. doi:10.1007/s10637-005-4540-2
-
(2006)
Invest New Drugs
, vol.24
, pp. 27-36
-
-
van Laarhoven, H.W.1
Gambarota, G.2
Heerschap, A.3
Lok, J.4
Verhagen, I.5
Corti, A.6
-
53
-
-
84863007720
-
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
-
doi:10.1038/bjc.2012.233
-
Lorusso D, Scambia G, Amadio G, Di Legge A, Pietragalla A, De Vincenzo R, et al. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br J Cancer (2012) 107:37-42. doi:10.1038/bjc.2012.233
-
(2012)
Br J Cancer
, vol.107
, pp. 37-42
-
-
Lorusso, D.1
Scambia, G.2
Amadio, G.3
Di Legge, A.4
Pietragalla, A.5
De Vincenzo, R.6
-
54
-
-
10744221996
-
Selective targeted delivery of TNFalpha to tumor blood vessels
-
doi:10.1182/blood-2003-04-1039
-
Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 102:4384-92. doi:10.1182/blood-2003-04-1039
-
(2003)
Blood
, vol.102
, pp. 4384-4392
-
-
Borsi, L.1
Balza, E.2
Carnemolla, B.3
Sassi, F.4
Castellani, P.5
Berndt, A.6
-
55
-
-
2442621619
-
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
-
doi:10.1038/nrd1381
-
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 3:391-400. doi:10.1038/nrd1381
-
(2004)
Nat Rev Drug Discov
, vol.3
, pp. 391-400
-
-
Ferrara, N.1
Hillan, K.J.2
Gerber, H.P.3
Novotny, W.4
-
56
-
-
0037448353
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
-
doi:10.1056/NEJMoa020177
-
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 348:203-13. doi:10.1056/NEJMoa020177
-
(2003)
N Engl J Med
, vol.348
, pp. 203-213
-
-
Zhang, L.1
Conejo-Garcia, J.R.2
Katsaros, D.3
Gimotty, P.A.4
Massobrio, M.5
Regnani, G.6
-
57
-
-
84858785703
-
Coordinated regulation of myeloid cells by tumours
-
doi:10.1038/nri3175
-
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12:253-68. doi:10.1038/nri3175
-
(2012)
Nat Rev Immunol
, vol.12
, pp. 253-268
-
-
Gabrilovich, D.I.1
Ostrand-Rosenberg, S.2
Bronte, V.3
-
58
-
-
33645286546
-
Regulatory T cells, tumour immunity and immunotherapy
-
doi:10.1038/nri1806
-
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 6:295-307. doi:10.1038/nri1806
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 295-307
-
-
Zou, W.1
-
59
-
-
33947259319
-
Immunosuppressive strategies that are mediated by tumor cells
-
doi:10.1146/annurev.immunol.25.022106.141609
-
Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 25:267-96. doi:10.1146/annurev.immunol.25.022106.141609
-
(2007)
Annu Rev Immunol
, vol.25
, pp. 267-296
-
-
Rabinovich, G.A.1
Gabrilovich, D.2
Sotomayor, E.M.3
-
60
-
-
33646231504
-
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors
-
doi:10.1096/fj.05-4493com
-
Dirkx AEM, Oude Egbrink MGA, Castermans K, Van Der Schaft DWJ, Thijssen VLJL, Dings RPM, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 20:621-30. doi:10.1096/fj.05-4493com
-
(2006)
FASEB J
, vol.20
, pp. 621-630
-
-
Dirkx, A.E.M.1
Oude Egbrink, M.G.A.2
Castermans, K.3
Van Der Schaft, D.W.J.4
Thijssen, V.L.J.L.5
Dings, R.P.M.6
-
61
-
-
33845343558
-
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy
-
doi:10.1158/1078-0432.CCR-06-1558
-
Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res (2006) 12:6808-16. doi:10.1158/1078-0432.CCR-06-1558
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6808-6816
-
-
Li, B.1
Lalani, A.S.2
Harding, T.C.3
Luan, B.4
Koprivnikar, K.5
Huan Tu, G.6
-
62
-
-
77955406159
-
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
-
doi:10.1158/0008-5472.CAN-10-0153
-
Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 70:6171-80. doi:10.1158/0008-5472.CAN-10-0153
-
(2010)
Cancer Res
, vol.70
, pp. 6171-6180
-
-
Shrimali, R.K.1
Yu, Z.2
Theoret, M.R.3
Chinnasamy, D.4
Restifo, N.P.5
Rosenberg, S.A.6
-
63
-
-
84867902940
-
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
-
doi:10.1073/pnas.1215397109
-
Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 109:17561-6. doi:10.1073/pnas.1215397109
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 17561-17566
-
-
Huang, Y.1
Yuan, J.2
Righi, E.3
Kamoun, W.S.4
Ancukiewicz, M.5
Nezivar, J.6
-
64
-
-
0033782775
-
Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
-
doi:10.1038/80506
-
Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med (2000) 6:1160-6. doi:10.1038/80506
-
(2000)
Nat Med
, vol.6
, pp. 1160-1166
-
-
Wei, Y.Q.1
Wang, Q.R.2
Zhao, X.3
Yang, L.4
Tian, L.5
Lu, Y.6
-
65
-
-
78049436238
-
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
-
doi:10.1172/JCI43490
-
Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 120:3953-68. doi:10.1172/JCI43490
-
(2010)
J Clin Invest
, vol.120
, pp. 3953-3968
-
-
Chinnasamy, D.1
Yu, Z.2
Theoret, M.R.3
Zhao, Y.4
Shrimali, R.K.5
Morgan, R.A.6
-
66
-
-
84878588973
-
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice
-
doi:10.1158/0008-5472.CAN-12-3913
-
Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res (2013) 73:3371-80. doi:10.1158/0008-5472.CAN-12-3913
-
(2013)
Cancer Res
, vol.73
, pp. 3371-3380
-
-
Chinnasamy, D.1
Tran, E.2
Yu, Z.3
Morgan, R.A.4
Restifo, N.P.5
Rosenberg, S.A.6
-
67
-
-
5444225991
-
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
-
doi:10.1016/j.ccr.2004.08.031
-
Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 6:409-21. doi:10.1016/j.ccr.2004.08.031
-
(2004)
Cancer Cell
, vol.6
, pp. 409-421
-
-
Yang, L.1
Debusk, L.M.2
Fukuda, K.3
Fingleton, B.4
Green-Jarvis, B.5
Shyr, Y.6
-
68
-
-
74249123434
-
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
-
doi:10.1002/eji.200939887
-
Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol (2010) 40:197-203. doi:10.1002/eji.200939887
-
(2010)
Eur J Immunol
, vol.40
, pp. 197-203
-
-
Suzuki, H.1
Onishi, H.2
Wada, J.3
Yamasaki, A.4
Tanaka, H.5
Nakano, K.6
-
69
-
-
77952310126
-
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
-
doi:10.1200/JCO.2009.27.2757
-
Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol (2010) 28:2280-5. doi:10.1200/JCO.2009.27.2757
-
(2010)
J Clin Oncol
, vol.28
, pp. 2280-2285
-
-
Choueiri, T.K.1
Schutz, F.A.2
Je, Y.3
Rosenberg, J.E.4
Bellmunt, J.5
-
70
-
-
77951764520
-
Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors
-
doi:10.1158/0008-5472.CAN-09-4253
-
Hess Michelini R, Freschi M, Manzo T, Jachetti E, Degl'Innocenti E, Grioni M, et al. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res (2010) 70:3505-14. doi:10.1158/0008-5472.CAN-09-4253
-
(2010)
Cancer Res
, vol.70
, pp. 3505-3514
-
-
Hess Michelini, R.1
Freschi, M.2
Manzo, T.3
Jachetti, E.4
Degl'Innocenti, E.5
Grioni, M.6
-
71
-
-
84881420066
-
Vaccine-instructed intratumoral IFN-gamma enables regression of autochthonous mouse prostate cancer in allogeneic T cell transplantation
-
doi:10.1158/0008-5472.CAN-12-3464
-
Hess Michelini R, Manzo T, Sturmheit T, Basso V, Rocchi M, Freschi M, et al. Vaccine-instructed intratumoral IFN-gamma enables regression of autochthonous mouse prostate cancer in allogeneic T cell transplantation. Cancer Res (2013) 73(15):4641-52. doi:10.1158/0008-5472.CAN-12-3464
-
(2013)
Cancer Res
, vol.73
, Issue.15
, pp. 4641-4652
-
-
Hess Michelini, R.1
Manzo, T.2
Sturmheit, T.3
Basso, V.4
Rocchi, M.5
Freschi, M.6
-
72
-
-
18344375283
-
Immunotherapy and chemotherapy-a practical partnership
-
doi:10.1038/nrc1613
-
Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer (2005) 5:397-405. doi:10.1038/nrc1613
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 397-405
-
-
Lake, R.A.1
Robinson, B.W.2
-
74
-
-
84860521444
-
The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
-
doi:10.1158/0008-5472.CAN-11-3538
-
Abastado JP. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res (2012) 72:2159-61. doi:10.1158/0008-5472.CAN-11-3538
-
(2012)
Cancer Res
, vol.72
, pp. 2159-2161
-
-
Abastado, J.P.1
-
75
-
-
85006768050
-
The metabolism of tumors in the body
-
doi:10.1085/jgp.8.6.519
-
Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol (1927) 8:519-30. doi:10.1085/jgp.8.6.519
-
(1927)
J Gen Physiol
, vol.8
, pp. 519-530
-
-
Warburg, O.1
Wind, F.2
Negelein, E.3
-
76
-
-
0038269105
-
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation
-
doi:10.1074/jbc.M212741200
-
Cham CM, Xu H, O'Keefe JP, Rivas FV, Zagouras P, Gajewski TF. Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem (2003) 278:17044-52. doi:10.1074/jbc.M212741200
-
(2003)
J Biol Chem
, vol.278
, pp. 17044-17052
-
-
Cham, C.M.1
Xu, H.2
O'Keefe, J.P.3
Rivas, F.V.4
Zagouras, P.5
Gajewski, T.F.6
-
77
-
-
18244395827
-
Metabolic mechanisms of tumor resistance to T cell effector function
-
doi:10.1385/IR:31:2:107
-
Cham CM, Gajewski TF. Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res (2005) 31:107-18. doi:10.1385/IR:31:2:107
-
(2005)
Immunol Res
, vol.31
, pp. 107-118
-
-
Cham, C.M.1
Gajewski, T.F.2
-
78
-
-
8144228566
-
Why do cancers have high aerobic glycolysis?
-
doi:10.1038/nrc1478
-
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 4:891-9. doi:10.1038/nrc1478
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 891-899
-
-
Gatenby, R.A.1
Gillies, R.J.2
-
79
-
-
38849143765
-
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators
-
doi:10.1038/nrd2467
-
Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov (2008) 7:168-81. doi:10.1038/nrd2467
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 168-181
-
-
Supuran, C.T.1
-
80
-
-
58249094845
-
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH
-
doi:10.1158/0008-5472.CAN-08-2470
-
Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res (2009) 69:358-68. doi:10.1158/0008-5472.CAN-08-2470
-
(2009)
Cancer Res
, vol.69
, pp. 358-368
-
-
Chiche, J.1
Ilc, K.2
Laferriere, J.3
Trottier, E.4
Dayan, F.5
Mazure, N.M.6
-
81
-
-
0030614893
-
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation
-
doi:10.1038/nm0297-177
-
Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 3:177-82. doi:10.1038/nm0297-177
-
(1997)
Nat Med
, vol.3
, pp. 177-182
-
-
Helmlinger, G.1
Yuan, F.2
Dellian, M.3
Jain, R.K.4
-
82
-
-
36349001899
-
Targeting vacuolar H+-ATPases as a new strategy against cancer
-
doi:10.1158/0008-5472.CAN-07-1805
-
Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res (2007) 67:10627-30. doi:10.1158/0008-5472.CAN-07-1805
-
(2007)
Cancer Res
, vol.67
, pp. 10627-10630
-
-
Fais, S.1
De Milito, A.2
You, H.3
Qin, W.4
-
83
-
-
44349157832
-
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
-
doi:10.1038/nrc2397
-
Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 8:425-37. doi:10.1038/nrc2397
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 425-437
-
-
Dewhirst, M.W.1
Cao, Y.2
Moeller, B.3
-
84
-
-
73449121970
-
Redox-based escape mechanism from death: the cancer lesson
-
doi:10.1089/ars.2009.2739
-
Pani G, Giannoni E, Galeotti T, Chiarugi P. Redox-based escape mechanism from death: the cancer lesson. Antioxid Redox Signal (2009) 11:2791-806. doi:10.1089/ars.2009.2739
-
(2009)
Antioxid Redox Signal
, vol.11
, pp. 2791-2806
-
-
Pani, G.1
Giannoni, E.2
Galeotti, T.3
Chiarugi, P.4
-
85
-
-
33751178410
-
The thioredoxin system in cancer
-
doi:10.1016/j.semcancer.2006.10.009
-
Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol (2006) 16:420-6. doi:10.1016/j.semcancer.2006.10.009
-
(2006)
Semin Cancer Biol
, vol.16
, pp. 420-426
-
-
Arner, E.S.1
Holmgren, A.2
-
86
-
-
51949087589
-
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants
-
doi:10.1002/ijc.23709
-
Ceccarelli J, Delfino L, Zappia E, Castellani P, Borghi M, Ferrini S, et al. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer (2008) 123:1770-8. doi:10.1002/ijc.23709
-
(2008)
Int J Cancer
, vol.123
, pp. 1770-1778
-
-
Ceccarelli, J.1
Delfino, L.2
Zappia, E.3
Castellani, P.4
Borghi, M.5
Ferrini, S.6
-
87
-
-
31544467810
-
Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer
-
doi:10.1158/0008-5472.CAN-05-1357
-
Csiki I, Yanagisawa K, Haruki N, Nadaf S, Morrow JD, Johnson DH, et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res (2006) 66:143-50. doi:10.1158/0008-5472.CAN-05-1357
-
(2006)
Cancer Res
, vol.66
, pp. 143-150
-
-
Csiki, I.1
Yanagisawa, K.2
Haruki, N.3
Nadaf, S.4
Morrow, J.D.5
Johnson, D.H.6
-
88
-
-
34347207246
-
Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species
-
doi:10.1158/0008-5472.CAN-06-4095
-
De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res (2007) 67:5408-17. doi:10.1158/0008-5472.CAN-06-4095
-
(2007)
Cancer Res
, vol.67
, pp. 5408-5417
-
-
De Milito, A.1
Iessi, E.2
Logozzi, M.3
Lozupone, F.4
Spada, M.5
Marino, M.L.6
-
89
-
-
84876771596
-
The immune system as a sensor of the metabolic state
-
doi:10.1016/j.immuni.2013.04.001
-
Odegaard JI, Chawla A. The immune system as a sensor of the metabolic state. Immunity (2013) 38:644-54. doi:10.1016/j.immuni.2013.04.001
-
(2013)
Immunity
, vol.38
, pp. 644-654
-
-
Odegaard, J.I.1
Chawla, A.2
-
90
-
-
84875261622
-
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
-
doi:10.1016/j.it.2012.10.001
-
Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2013) 34:137-43. doi:10.1016/j.it.2012.10.001
-
(2013)
Trends Immunol
, vol.34
, pp. 137-143
-
-
Munn, D.H.1
Mellor, A.L.2
-
91
-
-
84880664259
-
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
-
doi:10.1084/jem.20130066
-
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 210:1389-402. doi:10.1084/jem.20130066
-
(2013)
J Exp Med
, vol.210
, pp. 1389-1402
-
-
Holmgaard, R.B.1
Zamarin, D.2
Munn, D.H.3
Wolchok, J.D.4
Allison, J.P.5
-
92
-
-
0035575975
-
Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions
-
Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol (2001) 167:6140-9.
-
(2001)
J Immunol
, vol.167
, pp. 6140-6149
-
-
Caldwell, C.C.1
Kojima, H.2
Lukashev, D.3
Armstrong, J.4
Farber, M.5
Apasov, S.G.6
-
93
-
-
0037438642
-
Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation
-
Conforti L, Petrovic M, Mohammad D, Lee S, Ma Q, Barone S, et al. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation. J Immunol (2003) 170:695-702.
-
(2003)
J Immunol
, vol.170
, pp. 695-702
-
-
Conforti, L.1
Petrovic, M.2
Mohammad, D.3
Lee, S.4
Ma, Q.5
Barone, S.6
-
94
-
-
33749512970
-
Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes
-
Lukashev D, Klebanov B, Kojima H, Grinberg A, Ohta A, Berenfeld L, et al. Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 177:4962-5.
-
(2006)
J Immunol
, vol.177
, pp. 4962-4965
-
-
Lukashev, D.1
Klebanov, B.2
Kojima, H.3
Grinberg, A.4
Ohta, A.5
Berenfeld, L.6
-
95
-
-
36849008476
-
Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival
-
doi:10.1371/journal.pone.0000853
-
Thiel M, Caldwell CC, Kreth S, Kuboki S, Chen P, Smith P, et al. Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS ONE (2007) 2:e853. doi:10.1371/journal.pone.0000853
-
(2007)
PLoS ONE
, vol.2
-
-
Thiel, M.1
Caldwell, C.C.2
Kreth, S.3
Kuboki, S.4
Chen, P.5
Smith, P.6
-
96
-
-
58149147369
-
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia
-
doi:10.1158/1078-0432.CCR-08-0229
-
Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 14:5947-52. doi:10.1158/1078-0432.CCR-08-0229
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5947-5952
-
-
Sitkovsky, M.V.1
Kjaergaard, J.2
Lukashev, D.3
Ohta, A.4
-
97
-
-
79960393113
-
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells
-
doi:10.1038/nature10169
-
Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 475:226-30. doi:10.1038/nature10169
-
(2011)
Nature
, vol.475
, pp. 226-230
-
-
Facciabene, A.1
Peng, X.2
Hagemann, I.S.3
Balint, K.4
Barchetti, A.5
Wang, L.P.6
-
98
-
-
80052277906
-
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1
-
doi:10.1016/j.cell.2011.07.033
-
Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146:772-84. doi:10.1016/j.cell.2011.07.033
-
(2011)
Cell
, vol.146
, pp. 772-784
-
-
Dang, E.V.1
Barbi, J.2
Yang, H.Y.3
Jinasena, D.4
Yu, H.5
Zheng, Y.6
-
99
-
-
79960369458
-
HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells
-
doi:10.1084/jem.20110278
-
Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208:1367-76. doi:10.1084/jem.20110278
-
(2011)
J Exp Med
, vol.208
, pp. 1367-1376
-
-
Shi, L.Z.1
Wang, R.2
Huang, G.3
Vogel, P.4
Neale, G.5
Green, D.R.6
-
100
-
-
79955040909
-
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer
-
doi:10.4049/jimmunol.1003251
-
Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 186:4388-95. doi:10.4049/jimmunol.1003251
-
(2011)
J Immunol
, vol.186
, pp. 4388-4395
-
-
Kryczek, I.1
Wu, K.2
Zhao, E.3
Wei, S.4
Vatan, L.5
Szeliga, W.6
-
101
-
-
84873691650
-
The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin
-
doi:10.1146/annurev-pathol-011110-130318
-
Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol (2013) 8:477-512. doi:10.1146/annurev-pathol-011110-130318
-
(2013)
Annu Rev Pathol
, vol.8
, pp. 477-512
-
-
Weaver, C.T.1
Elson, C.O.2
Fouser, L.A.3
Kolls, J.K.4
-
102
-
-
70449530422
-
T helper 17 cells promote cytotoxic T cell activation in tumor immunity
-
doi:10.1016/j.immuni.2009.09.014
-
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 31:787-98. doi:10.1016/j.immuni.2009.09.014
-
(2009)
Immunity
, vol.31
, pp. 787-798
-
-
Martin-Orozco, N.1
Muranski, P.2
Chung, Y.3
Yang, X.O.4
Yamazaki, T.5
Lu, S.6
-
103
-
-
77950196277
-
T(H)17 cells in tumour immunity and immunotherapy
-
doi:10.1038/nri2742
-
Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 10:248-56. doi:10.1038/nri2742
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 248-256
-
-
Zou, W.1
Restifo, N.P.2
-
104
-
-
84866361046
-
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells
-
doi:10.1158/0008-5472.CAN-12-1383
-
Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 72:4629-41. doi:10.1158/0008-5472.CAN-12-1383
-
(2012)
Cancer Res
, vol.72
, pp. 4629-4641
-
-
Noman, M.Z.1
Buart, S.2
Romero, P.3
Ketari, S.4
Janji, B.5
Mari, B.6
-
105
-
-
0017384820
-
Energy metabolism and T-cell-mediated cytolysis. II. Selective inhibition of cytolysis by 2-deoxy-d-glucose
-
doi:10.1084/jem.146.3.710
-
MacDonald HR. Energy metabolism and T-cell-mediated cytolysis. II. Selective inhibition of cytolysis by 2-deoxy-d-glucose. J Exp Med (1977) 146:710-9. doi:10.1084/jem.146.3.710
-
(1977)
J Exp Med
, vol.146
, pp. 710-719
-
-
MacDonald, H.R.1
-
106
-
-
0035071662
-
The effects of extracellular pH on immune function
-
Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol (2001) 69:522-30.
-
(2001)
J Leukoc Biol
, vol.69
, pp. 522-530
-
-
Lardner, A.1
-
107
-
-
39149122935
-
Metabolic acidosis in patients with sepsis: epiphenomenon or part of the pathophysiology?
-
Kellum JA. Metabolic acidosis in patients with sepsis: epiphenomenon or part of the pathophysiology? Crit Care Resusc (2004) 6:197-203.
-
(2004)
Crit Care Resusc
, vol.6
, pp. 197-203
-
-
Kellum, J.A.1
-
108
-
-
33645750798
-
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells
-
doi:10.1158/0008-5472.CAN-05-3204
-
Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res (2006) 66:3629-38. doi:10.1158/0008-5472.CAN-05-3204
-
(2006)
Cancer Res
, vol.66
, pp. 3629-3638
-
-
Lugini, L.1
Matarrese, P.2
Tinari, A.3
Lozupone, F.4
Federici, C.5
Iessi, E.6
-
109
-
-
0023245199
-
Regulation of T-cell functions by l-lactate
-
doi:10.1016/0008-8749(87)90223-1
-
Droge W, Roth S, Altmann A, Mihm S. Regulation of T-cell functions by l-lactate. Cell Immunol (1987) 108:405-16. doi:10.1016/0008-8749(87)90223-1
-
(1987)
Cell Immunol
, vol.108
, pp. 405-416
-
-
Droge, W.1
Roth, S.2
Altmann, A.3
Mihm, S.4
-
110
-
-
0025261897
-
Lymphocytes stimulated with recombinant human interleukin-2: relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice
-
doi:10.1093/jnci/82.7.612
-
Ratner S. Lymphocytes stimulated with recombinant human interleukin-2: relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice. J Natl Cancer Inst (1990) 82:612-6. doi:10.1093/jnci/82.7.612
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 612-616
-
-
Ratner, S.1
-
111
-
-
0025721115
-
Comparative studies of the cytotoxic T lymphocyte-mediated cytotoxicity and of extracellular ATP-induced cell lysis. Different requirements in extracellular Mg2+ and pH
-
Redegeld F, Filippini A, Sitkovsky M. Comparative studies of the cytotoxic T lymphocyte-mediated cytotoxicity and of extracellular ATP-induced cell lysis. Different requirements in extracellular Mg2+ and pH. J Immunol (1991) 147:3638-45.
-
(1991)
J Immunol
, vol.147
, pp. 3638-3645
-
-
Redegeld, F.1
Filippini, A.2
Sitkovsky, M.3
-
112
-
-
34247352844
-
Inhibitory effect of tumor cell-derived lactic acid on human T cells
-
doi:10.1182/blood-2006-07-035972
-
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 109:3812-9. doi:10.1182/blood-2006-07-035972
-
(2007)
Blood
, vol.109
, pp. 3812-3819
-
-
Fischer, K.1
Hoffmann, P.2
Voelkl, S.3
Meidenbauer, N.4
Ammer, J.5
Edinger, M.6
-
113
-
-
84861861104
-
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes
-
doi:10.1158/0008-5472.CAN-11-1272
-
Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 72:2746-56. doi:10.1158/0008-5472.CAN-11-1272
-
(2012)
Cancer Res
, vol.72
, pp. 2746-2756
-
-
Calcinotto, A.1
Filipazzi, P.2
Grioni, M.3
Iero, M.4
De Milito, A.5
Ricupito, A.6
-
114
-
-
0034142187
-
IL-2 unresponsiveness in anergic CD4+ T cells is due to defective signaling through the common gamma-chain of the IL-2 receptor
-
Grundstrom S, Dohlsten M, Sundstedt A. IL-2 unresponsiveness in anergic CD4+ T cells is due to defective signaling through the common gamma-chain of the IL-2 receptor. J Immunol (2000) 164:1175-84.
-
(2000)
J Immunol
, vol.164
, pp. 1175-1184
-
-
Grundstrom, S.1
Dohlsten, M.2
Sundstedt, A.3
-
115
-
-
0034283927
-
T cell effector function and anergy avoidance are quantitatively linked to cell division
-
Wells AD, Walsh MC, Sankaran D, Turka LA. T cell effector function and anergy avoidance are quantitatively linked to cell division. J Immunol (2000) 165:2432-43.
-
(2000)
J Immunol
, vol.165
, pp. 2432-2443
-
-
Wells, A.D.1
Walsh, M.C.2
Sankaran, D.3
Turka, L.A.4
-
116
-
-
84886945702
-
The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors
-
doi:10.4161/onci.22058
-
Bellone M, Calcinotto A, Filipazzi P, De Milito A, Fais S, Rivoltini L. The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. Oncoimmunology (2013) 2:e22058. doi:10.4161/onci.22058
-
(2013)
Oncoimmunology
, vol.2
-
-
Bellone, M.1
Calcinotto, A.2
Filipazzi, P.3
De Milito, A.4
Fais, S.5
Rivoltini, L.6
-
117
-
-
0015596284
-
Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent
-
doi:10.1172/JCI107236
-
Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest (1973) 52:741-4. doi:10.1172/JCI107236
-
(1973)
J Clin Invest
, vol.52
, pp. 741-744
-
-
Babior, B.M.1
Kipnes, R.S.2
Curnutte, J.T.3
-
118
-
-
84868314921
-
Redox control of NLRP3 inflammasome activation in health and disease
-
doi:10.1189/jlb.0512265
-
Rubartelli A. Redox control of NLRP3 inflammasome activation in health and disease. J Leukoc Biol (2012) 92:951-8. doi:10.1189/jlb.0512265
-
(2012)
J Leukoc Biol
, vol.92
, pp. 951-958
-
-
Rubartelli, A.1
-
119
-
-
4444240314
-
T cell receptor stimulation, reactive oxygen species, and cell signaling
-
doi:10.1016/j.freeradbiomed.2004.05.029
-
Williams MS, Kwon J. T cell receptor stimulation, reactive oxygen species, and cell signaling. Free Radic Biol Med (2004) 37:1144-51. doi:10.1016/j.freeradbiomed.2004.05.029
-
(2004)
Free Radic Biol Med
, vol.37
, pp. 1144-1151
-
-
Williams, M.S.1
Kwon, J.2
-
120
-
-
0032533159
-
Arginine metabolism: nitric oxide and beyond
-
Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 336(Pt 1):1-17.
-
(1998)
Biochem J
, vol.336
, Issue.PART 1
, pp. 1-17
-
-
Wu, G.1
Morris Jr., S.M.2
-
121
-
-
0034769118
-
Nitric oxide and the immune response
-
doi:10.1038/35098532
-
Bogdan C. Nitric oxide and the immune response. Nat Immunol (2001) 2:907-16. doi:10.1038/35098532
-
(2001)
Nat Immunol
, vol.2
, pp. 907-916
-
-
Bogdan, C.1
-
122
-
-
0037077192
-
Regulation of T cell receptor CD3zeta chain expression by l-arginine
-
doi:10.1074/jbc.M110675200
-
Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem (2002) 277:21123-9. doi:10.1074/jbc.M110675200
-
(2002)
J Biol Chem
, vol.277
, pp. 21123-21129
-
-
Rodriguez, P.C.1
Zea, A.H.2
Culotta, K.S.3
Zabaleta, J.4
Ochoa, J.B.5
Ochoa, A.C.6
-
123
-
-
4143130091
-
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
-
doi:10.1158/0008-5472.CAN-04-0465
-
Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 64:5839-49. doi:10.1158/0008-5472.CAN-04-0465
-
(2004)
Cancer Res
, vol.64
, pp. 5839-5849
-
-
Rodriguez, P.C.1
Quiceno, D.G.2
Zabaleta, J.3
Ortiz, B.4
Zea, A.H.5
Piazuelo, M.B.6
-
124
-
-
33846933459
-
l-arginine availability regulates T-lymphocyte cell-cycle progression
-
doi:10.1182/blood-2006-06-031856
-
Rodriguez PC, Quiceno DG, Ochoa AC. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2007) 109:1568-73. doi:10.1182/blood-2006-06-031856
-
(2007)
Blood
, vol.109
, pp. 1568-1573
-
-
Rodriguez, P.C.1
Quiceno, D.G.2
Ochoa, A.C.3
-
125
-
-
0032526629
-
Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway
-
Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol (1998) 160:5729-34.
-
(1998)
J Immunol
, vol.160
, pp. 5729-5734
-
-
Bingisser, R.M.1
Tilbrook, P.A.2
Holt, P.G.3
Kees, U.R.4
-
126
-
-
0037080021
-
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism
-
Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 168:689-95.
-
(2002)
J Immunol
, vol.168
, pp. 689-695
-
-
Mazzoni, A.1
Bronte, V.2
Visintin, A.3
Spitzer, J.H.4
Apolloni, E.5
Serafini, P.6
-
127
-
-
0028316846
-
Nitric oxide involvement in tumor-induced immunosuppression
-
Lejeune P, Lagadec P, Onier N, Pinard D, Ohshima H, Jeannin JF. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol (1994) 152:5077-83.
-
(1994)
J Immunol
, vol.152
, pp. 5077-5083
-
-
Lejeune, P.1
Lagadec, P.2
Onier, N.3
Pinard, D.4
Ohshima, H.5
Jeannin, J.F.6
-
128
-
-
0033179327
-
Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction
-
Bobe P, Benihoud K, Grandjon D, Opolon P, Pritchard LL, Huchet R. Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood (1999) 94:1028-37.
-
(1999)
Blood
, vol.94
, pp. 1028-1037
-
-
Bobe, P.1
Benihoud, K.2
Grandjon, D.3
Opolon, P.4
Pritchard, L.L.5
Huchet, R.6
-
129
-
-
33846006154
-
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells
-
doi:10.1182/blood-2006-02-002246
-
Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood (2007) 109:228-34. doi:10.1182/blood-2006-02-002246
-
(2007)
Blood
, vol.109
, pp. 228-234
-
-
Sato, K.1
Ozaki, K.2
Oh, I.3
Meguro, A.4
Hatanaka, K.5
Nagai, T.6
-
130
-
-
0032475865
-
Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process
-
doi:10.1074/jbc.273.40.25804
-
Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem (1998) 273:25804-8. doi:10.1074/jbc.273.40.25804
-
(1998)
J Biol Chem
, vol.273
, pp. 25804-25808
-
-
Xia, Y.1
Tsai, A.L.2
Berka, V.3
Zweier, J.L.4
-
131
-
-
0037223170
-
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice
-
Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 170:270-8.
-
(2003)
J Immunol
, vol.170
, pp. 270-278
-
-
Bronte, V.1
Serafini, P.2
De Santo, C.3
Marigo, I.4
Tosello, V.5
Mazzoni, A.6
-
132
-
-
28044445899
-
Role of immature myeloid cells in mechanisms of immune evasion in cancer
-
doi:10.1007/s00262-005-0048-z
-
Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2006) 55:237-45. doi:10.1007/s00262-005-0048-z
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 237-245
-
-
Kusmartsev, S.1
Gabrilovich, D.I.2
-
133
-
-
0028947405
-
The formation of peroxynitrite in vivo from nitric oxide and superoxide
-
doi:10.1016/0009-2797(94)03591-U
-
Squadrito GL, Pryor WA. The formation of peroxynitrite in vivo from nitric oxide and superoxide. Chem Biol Interact (1995) 96:203-6. doi:10.1016/0009-2797(94)03591-U
-
(1995)
Chem Biol Interact
, vol.96
, pp. 203-206
-
-
Squadrito, G.L.1
Pryor, W.A.2
-
134
-
-
34447118098
-
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
-
doi:10.1038/nm1609
-
Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 13:828-35. doi:10.1038/nm1609
-
(2007)
Nat Med
, vol.13
, pp. 828-835
-
-
Nagaraj, S.1
Gupta, K.2
Pisarev, V.3
Kinarsky, L.4
Sherman, S.5
Kang, L.6
-
135
-
-
80054694464
-
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
-
doi:10.1084/jem.20101956
-
Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 208:1949-62. doi:10.1084/jem.20101956
-
(2011)
J Exp Med
, vol.208
, pp. 1949-1962
-
-
Molon, B.1
Ugel, S.2
Del Pozzo, F.3
Soldani, C.4
Zilio, S.5
Avella, D.6
-
136
-
-
70349314830
-
Extracellular redox modulation by regulatory T cells
-
doi:10.1038/nchembio.212
-
Yan Z, Garg SK, Kipnis J, Banerjee R. Extracellular redox modulation by regulatory T cells. Nat Chem Biol (2009) 5:721-3. doi:10.1038/nchembio.212
-
(2009)
Nat Chem Biol
, vol.5
, pp. 721-723
-
-
Yan, Z.1
Garg, S.K.2
Kipnis, J.3
Banerjee, R.4
-
137
-
-
0037022345
-
Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation
-
doi:10.1073/pnas.022630299
-
Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A (2002) 99:1491-6. doi:10.1073/pnas.022630299
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 1491-1496
-
-
Angelini, G.1
Gardella, S.2
Ardy, M.3
Ciriolo, M.R.4
Filomeni, G.5
Di Trapani, G.6
-
138
-
-
78650651362
-
Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells
-
doi:10.1074/jbc.M110.189944
-
Yan Z, Garg SK, Banerjee R. Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. J Biol Chem (2010) 285:41525-32. doi:10.1074/jbc.M110.189944
-
(2010)
J Biol Chem
, vol.285
, pp. 41525-41532
-
-
Yan, Z.1
Garg, S.K.2
Banerjee, R.3
-
139
-
-
33750832563
-
T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine
-
Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 177:6780-6.
-
(2006)
J Immunol
, vol.177
, pp. 6780-6786
-
-
Kobie, J.J.1
Shah, P.R.2
Yang, L.3
Rebhahn, J.A.4
Fowell, D.J.5
Mosmann, T.R.6
-
140
-
-
34250351459
-
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
-
doi:10.1084/jem.20062512
-
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 204:1257-65. doi:10.1084/jem.20062512
-
(2007)
J Exp Med
, vol.204
, pp. 1257-1265
-
-
Deaglio, S.1
Dwyer, K.M.2
Gao, W.3
Friedman, D.4
Usheva, A.5
Erat, A.6
-
141
-
-
67650096912
-
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
-
doi:10.1038/nature08097
-
Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 460:103-7. doi:10.1038/nature08097
-
(2009)
Nature
, vol.460
, pp. 103-107
-
-
Pearce, E.L.1
Walsh, M.C.2
Cejas, P.J.3
Harms, G.M.4
Shen, H.5
Wang, L.S.6
-
142
-
-
79952740612
-
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
-
doi:10.1073/pnas.1014480108
-
Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 108:3749-54. doi:10.1073/pnas.1014480108
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 3749-3754
-
-
Keunen, O.1
Johansson, M.2
Oudin, A.3
Sanzey, M.4
Rahim, S.A.5
Fack, F.6
-
143
-
-
84857407549
-
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
-
doi:10.1073/pnas.1018866109
-
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 109:2784-9. doi:10.1073/pnas.1018866109
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 2784-2789
-
-
Conley, S.J.1
Gheordunescu, E.2
Kakarala, P.3
Newman, B.4
Korkaya, H.5
Heath, A.N.6
-
144
-
-
80052453669
-
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype
-
doi:10.1158/1078-0432.CCR-11-1185
-
Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res (2011) 17:5822-32. doi:10.1158/1078-0432.CCR-11-1185
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5822-5832
-
-
Carbone, C.1
Moccia, T.2
Zhu, C.3
Paradiso, G.4
Budillon, A.5
Chiao, P.J.6
-
145
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
doi:10.1016/j.ccr.2009.01.027
-
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 15:220-31. doi:10.1016/j.ccr.2009.01.027
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Paez-Ribes, M.1
Allen, E.2
Hudock, J.3
Takeda, T.4
Okuyama, H.5
Vinals, F.6
-
146
-
-
34547820876
-
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
-
doi:10.1038/nbt1323
-
Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 25:911-20. doi:10.1038/nbt1323
-
(2007)
Nat Biotechnol
, vol.25
, pp. 911-920
-
-
Shojaei, F.1
Wu, X.2
Malik, A.K.3
Zhong, C.4
Baldwin, M.E.5
Schanz, S.6
-
147
-
-
44849093414
-
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
-
doi:10.1093/annonc/mdm408
-
Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol (2007) 18(Suppl 10):x3-10. doi:10.1093/annonc/mdm408
-
(2007)
Ann Oncol
, vol.18
, Issue.SUPPL. 10
-
-
Christensen, J.G.1
-
148
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
doi:10.1200/JCO.2008.20.1293
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 27:3584-90. doi:10.1200/JCO.2008.20.1293
-
(2009)
J Clin Oncol
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Oudard, S.6
-
149
-
-
84860591982
-
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
-
doi:10.1172/JCI58976
-
Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest (2012) 122:1832-48. doi:10.1172/JCI58976
-
(2012)
J Clin Invest
, vol.122
, pp. 1832-1848
-
-
Maione, F.1
Capano, S.2
Regano, D.3
Zentilin, L.4
Giacca, M.5
Casanovas, O.6
-
150
-
-
58149179532
-
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
-
doi:10.1158/1078-0432.CCR-07-5212
-
Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 14:6674-82. doi:10.1158/1078-0432.CCR-07-5212
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6674-6682
-
-
Finke, J.H.1
Rini, B.2
Ireland, J.3
Rayman, P.4
Richmond, A.5
Golshayan, A.6
-
151
-
-
53249111806
-
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival
-
doi:10.1158/1078-0432.CCR-08-0656
-
van Cruijsen H, Van Der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 14:5884-92. doi:10.1158/1078-0432.CCR-08-0656
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5884-5892
-
-
van Cruijsen, H.1
Van Der Veldt, A.A.2
Vroling, L.3
Oosterhoff, D.4
Broxterman, H.J.5
Scheper, R.J.6
-
152
-
-
63549105681
-
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
-
doi:10.1158/1078-0432.CCR-08-1332
-
Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 15:2148-57. doi:10.1158/1078-0432.CCR-08-1332
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2148-2157
-
-
Ko, J.S.1
Zea, A.H.2
Rini, B.I.3
Ireland, J.L.4
Elson, P.5
Cohen, P.6
-
153
-
-
80054098093
-
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination
-
doi:10.1002/ijc.25863
-
Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 129:2158-70. doi:10.1002/ijc.25863
-
(2011)
Int J Cancer
, vol.129
, pp. 2158-2170
-
-
Bose, A.1
Taylor, J.L.2
Alber, S.3
Watkins, S.C.4
Garcia, J.A.5
Rini, B.I.6
-
154
-
-
84878999668
-
Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target
-
doi:10.4161/onci.19457
-
Pan F, Barbi J, Pardoll DM. Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target. Oncoimmunology (2012) 1:510-5. doi:10.4161/onci.19457
-
(2012)
Oncoimmunology
, vol.1
, pp. 510-515
-
-
Pan, F.1
Barbi, J.2
Pardoll, D.M.3
-
155
-
-
80054033683
-
Human TH17 cells are long-lived effector memory cells
-
104ra100. doi:10.1126/scitranslmed.3002949
-
Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 3:104ra100. doi:10.1126/scitranslmed.3002949
-
(2011)
Sci Transl Med
, vol.3
-
-
Kryczek, I.1
Zhao, E.2
Liu, Y.3
Wang, Y.4
Vatan, L.5
Szeliga, W.6
-
156
-
-
84866335513
-
The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy
-
doi:10.1158/2159-8290.CD-11-0314
-
Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 2:608-23. doi:10.1158/2159-8290.CD-11-0314
-
(2012)
Cancer Discov
, vol.2
, pp. 608-623
-
-
Palazon, A.1
Martinez-Forero, I.2
Teijeira, A.3
Morales-Kastresana, A.4
Alfaro, C.5
Sanmamed, M.F.6
-
157
-
-
65549166946
-
Bicarbonate increases tumor pH and inhibits spontaneous metastases
-
doi:10.1158/0008-5472.CAN-07-5575
-
Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 69:2260-8. doi:10.1158/0008-5472.CAN-07-5575
-
(2009)
Cancer Res
, vol.69
, pp. 2260-2268
-
-
Robey, I.F.1
Baggett, B.K.2
Kirkpatrick, N.D.3
Roe, D.J.4
Dosescu, J.5
Sloane, B.F.6
-
158
-
-
67649354220
-
Proton pump inhibitors: actions and reactions
-
doi:10.1016/j.drudis.2009.03.014
-
Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today (2009) 14:647-60. doi:10.1016/j.drudis.2009.03.014
-
(2009)
Drug Discov Today
, vol.14
, pp. 647-660
-
-
Mullin, J.M.1
Gabello, M.2
Murray, L.J.3
Farrell, C.P.4
Bellows, J.5
Wolov, K.R.6
-
159
-
-
77953463274
-
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity
-
doi:10.1002/ijc.25009
-
De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer (2010) 127:207-19. doi:10.1002/ijc.25009
-
(2010)
Int J Cancer
, vol.127
, pp. 207-219
-
-
De Milito, A.1
Canese, R.2
Marino, M.L.3
Borghi, M.4
Iero, M.5
Villa, A.6
-
160
-
-
70350212812
-
Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications
-
doi:10.1007/s10620-009-0951-9
-
Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci (2009) 54:2312-7. doi:10.1007/s10620-009-0951-9
-
(2009)
Dig Dis Sci
, vol.54
, pp. 2312-2317
-
-
Kedika, R.R.1
Souza, R.F.2
Spechler, S.J.3
-
161
-
-
84865147552
-
Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments
-
doi:10.1158/0008-5472.CAN-11-3881
-
Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, et al. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res (2012) 72:3938-47. doi:10.1158/0008-5472.CAN-11-3881
-
(2012)
Cancer Res
, vol.72
, pp. 3938-3947
-
-
Wojtkowiak, J.W.1
Rothberg, J.M.2
Kumar, V.3
Schramm, K.J.4
Haller, E.5
Proemsey, J.B.6
-
162
-
-
79958759965
-
Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells
-
doi:10.1038/cddis.2010.67
-
Marino ML, Fais S, Djavaheri-Mergny M, Villa A, Meschini S, Lozupone F, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis (2010) 1:e87. doi:10.1038/cddis.2010.67
-
(2010)
Cell Death Dis
, vol.1
-
-
Marino, M.L.1
Fais, S.2
Djavaheri-Mergny, M.3
Villa, A.4
Meschini, S.5
Lozupone, F.6
-
163
-
-
84865293299
-
Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity
-
doi:10.1111/j.1600-065X.2012.01141.x
-
Townsend KN, Hughson LR, Schlie K, Poon VI, Westerback A, Lum JJ. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev (2012) 249:176-94. doi:10.1111/j.1600-065X.2012.01141.x
-
(2012)
Immunol Rev
, vol.249
, pp. 176-194
-
-
Townsend, K.N.1
Hughson, L.R.2
Schlie, K.3
Poon, V.I.4
Westerback, A.5
Lum, J.J.6
-
164
-
-
79954623272
-
A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity
-
doi:10.1016/j.immuni.2011.04.006
-
Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 34:541-53. doi:10.1016/j.immuni.2011.04.006
-
(2011)
Immunity
, vol.34
, pp. 541-553
-
-
Li, Q.1
Rao, R.R.2
Araki, K.3
Pollizzi, K.4
Odunsi, K.5
Powell, J.D.6
-
165
-
-
84859400580
-
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity
-
doi:10.4049/jimmunol.1103365
-
Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, et al. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol (2012) 188:3080-7. doi:10.4049/jimmunol.1103365
-
(2012)
J Immunol
, vol.188
, pp. 3080-3087
-
-
Li, Q.1
Rao, R.2
Vazzana, J.3
Goedegebuure, P.4
Odunsi, K.5
Gillanders, W.6
-
166
-
-
33748357735
-
A2A adenosine receptor protects tumors from antitumor T cells
-
doi:10.1073/pnas.0605251103
-
Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 103:13132-7. doi:10.1073/pnas.0605251103
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 13132-13137
-
-
Ohta, A.1
Gorelik, E.2
Prasad, S.J.3
Ronchese, F.4
Lukashev, D.5
Wong, M.K.6
-
167
-
-
0028142291
-
Coffee and cancer: a prospective study of 43,000 Norwegian men and women
-
doi:10.1007/BF01694753
-
Stensvold I, Jacobsen BK. Coffee and cancer: a prospective study of 43,000 Norwegian men and women. Cancer Causes Control (1994) 5:401-8. doi:10.1007/BF01694753
-
(1994)
Cancer Causes Control
, vol.5
, pp. 401-408
-
-
Stensvold, I.1
Jacobsen, B.K.2
-
168
-
-
0030998210
-
Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women
-
doi:10.1002/(SICI)1097-0215(19970516)71:4<600::AID-IJC15>3.3.CO;2-C
-
Veierod MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer (1997) 71:600-4. doi:10.1002/(SICI)1097-0215(19970516)71:4<600::AID-IJC15>3.3.CO;2-C
-
(1997)
Int J Cancer
, vol.71
, pp. 600-604
-
-
Veierod, M.B.1
Thelle, D.S.2
Laake, P.3
-
169
-
-
35548950221
-
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy
-
doi:10.1038/nrc2250
-
Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 7:880-7. doi:10.1038/nrc2250
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 880-887
-
-
Colombo, M.P.1
Piconese, S.2
-
170
-
-
84874608992
-
Control of inflammation by integration of environmental cues by regulatory T cells
-
doi:10.1172/JCI57175
-
Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest (2013) 123:939-44. doi:10.1172/JCI57175
-
(2013)
J Clin Invest
, vol.123
, pp. 939-944
-
-
Chaudhry, A.1
Rudensky, A.Y.2
-
171
-
-
68849128500
-
Therapeutic targeting of myeloid-derived suppressor cells
-
doi:10.1016/j.coph.2009.06.014
-
Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol (2009) 9:470-81. doi:10.1016/j.coph.2009.06.014
-
(2009)
Curr Opin Pharmacol
, vol.9
, pp. 470-481
-
-
Ugel, S.1
Delpozzo, F.2
Desantis, G.3
Papalini, F.4
Simonato, F.5
Sonda, N.6
-
172
-
-
84856706929
-
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
-
doi:10.1007/s00262-011-1161-9
-
Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2012) 61:255-63. doi:10.1007/s00262-011-1161-9
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 255-263
-
-
Filipazzi, P.1
Huber, V.2
Rivoltini, L.3
-
173
-
-
41149148269
-
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
-
doi:10.1111/j.1600-065X.2008.00608.x
-
Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 222:180-91. doi:10.1111/j.1600-065X.2008.00608.x
-
(2008)
Immunol Rev
, vol.222
, pp. 180-191
-
-
Rodriguez, P.C.1
Ochoa, A.C.2
-
174
-
-
77957991455
-
Myeloid-derived suppressor cells in human cancer
-
doi:10.1097/PPO.0b013e3181eb3358
-
Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J (2010) 16:348-53. doi:10.1097/PPO.0b013e3181eb3358
-
(2010)
Cancer J
, vol.16
, pp. 348-353
-
-
Nagaraj, S.1
Gabrilovich, D.I.2
-
175
-
-
70249140303
-
Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells
-
doi:10.4049/jimmunol.0804253
-
Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 183:937-44. doi:10.4049/jimmunol.0804253
-
(2009)
J Immunol
, vol.183
, pp. 937-944
-
-
Hanson, E.M.1
Clements, V.K.2
Sinha, P.3
Ilkovitch, D.4
Ostrand-Rosenberg, S.5
-
176
-
-
42449123606
-
Natural killer cell-directed therapies: moving from unexpected results to successful strategies
-
doi:10.1038/ni1580
-
Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 9:486-94. doi:10.1038/ni1580
-
(2008)
Nat Immunol
, vol.9
, pp. 486-494
-
-
Terme, M.1
Ullrich, E.2
Delahaye, N.F.3
Chaput, N.4
Zitvogel, L.5
-
177
-
-
84862506395
-
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy
-
doi:10.1007/s00262-012-1216-6
-
Rigamonti N, Bellone M. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother (2012) 61:453-68. doi:10.1007/s00262-012-1216-6
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 453-468
-
-
Rigamonti, N.1
Bellone, M.2
-
178
-
-
84891053440
-
The tumor microenvironment and strategies to improve drug distribution
-
doi:10.3389/fonc.2013.00154
-
Saggar JK, Yu M, Tan Q, Tannock IF. The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 3:154. doi:10.3389/fonc.2013.00154
-
(2013)
Front Oncol
, vol.3
, pp. 154
-
-
Saggar, J.K.1
Yu, M.2
Tan, Q.3
Tannock, I.F.4
-
179
-
-
84886943622
-
Re-orienting the immune system: durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
-
doi:10.4161/onci.23661
-
Lipson EJ. Re-orienting the immune system: durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology (2013) 2:e23661. doi:10.4161/onci.23661
-
(2013)
Oncoimmunology
, vol.2
-
-
Lipson, E.J.1
-
180
-
-
59749089432
-
Targeted therapy for advanced colorectal cancer-more is not always better
-
doi:10.1056/NEJMe0809343
-
Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med (2009) 360:623-5. doi:10.1056/NEJMe0809343
-
(2009)
N Engl J Med
, vol.360
, pp. 623-625
-
-
Mayer, R.J.1
-
181
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
doi:10.1056/NEJMoa0808268
-
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 360:563-72. doi:10.1056/NEJMoa0808268
-
(2009)
N Engl J Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
Rodenburg, C.J.4
Creemers, G.J.5
Schrama, J.G.6
-
182
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
doi:10.1200/JCO.2008.19.8135
-
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2009) 27:672-80. doi:10.1200/JCO.2008.19.8135
-
(2009)
J Clin Oncol
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
Scroggin, C.4
Hagenstad, C.5
Spigel, D.6
|